Kidney Disease: Three Studies At-a-Glance

Slideshow

Highlighted: Chronic kidney disease and stroke risk, syphilis in ESRD patients, and how healthy diets may reduce CKD incidence.

In this slideshow, we bring you several highlights from recent research in kidney disease. Scroll through the slides below to find out more about chronic kidney disease (CKD) and stroke risk, syphilis incidence in end-stage renal disease (ESRD) patients and implications for screening, and how healthy diets may reduce the global burden of CKD. 

Recent Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

Lexicon Receives Complete Response Letter for Sotagliflozin in Type 1 Diabetes and Chronic Kidney Disease

Denise Myshko
January 3rd 2025
Article

In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease / image credit David Cherney UHN Research

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease

Grace Halsey
November 7th 2024
Article

The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD / image credit ©Tada Images/stock.adobe.com

Sotagliflozin Setback: Cautionary FDA AdComm Vote Reflects Continued Concern for Negative Risk/Benefit Ratio in T1D with CKD

Grace Halsey
November 1st 2024
Article

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 11 to 3 against recommending the SGLT1/SLGT2 inhibitor to treat adults with T1D and CKD.

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose / image credit: ©New Africa/AdobeStock

Oral Semaglutide Linked to Lower Risk of MACE: Daily Dose

Sydney Jennings
November 1st 2024
Article

Your daily dose of the clinical news you may have missed.

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024 / Image credit: ©Rasi/AdobeStock

New Data on Renal Protective Benefits of Sotagliflozin Will be Presented at Kidney Week 2024

Sydney Jennings
October 23rd 2024
Article

In a post hoc analysis of the SCORED trial, investigators observed positive renal protection with sotagliflozin across a spectrum of baseline kidney function and glycemic control.

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial / image credit heart and kidneys: ©krishnacreations/stock.adobe.com

Oral Semaglutide Shows 14% Reduction in MACE in Adults with T2D, ASCVD, and/or CKD: Topline Results from Phase 3 SOUL Trial

Grace Halsey
October 21st 2024
Article

Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.

© 2025 MJH Life Sciences

All rights reserved.